U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C16H11NO2.C4H10N2
Molecular Weight 335.3996
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CINCHOPHEN PIPERAZINE

SMILES

C1CNCCN1.OC(=O)C2=CC(=NC3=C2C=CC=C3)C4=CC=CC=C4

InChI

InChIKey=VGHQOUCHEAXCJT-UHFFFAOYSA-N
InChI=1S/C16H11NO2.C4H10N2/c18-16(19)13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14;1-2-6-4-3-5-1/h1-10H,(H,18,19);5-6H,1-4H2

HIDE SMILES / InChI

Molecular Formula C4H10N2
Molecular Weight 86.1356
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H11NO2
Molecular Weight 249.264
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.un.org/esa/coordination/CL12.pdf

Cinchophen, phenylcinchoninic acid, seems to have been discovered in 1887 by Doebner and Gieseke and to have been introduced into medicine under the trade name of atophan in 1908 by Nicolaier and Dohrn. Since that time it has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types. Use of Cinchophen in humans ceased in the 1930s due to the discovery that it can cause serious liver damage.

Originator

Curator's Comment: Cinchophen, phenylcinchoninic acid, seems to have been discovered in 1887 by Doebner and Gieseke and to have been introduced into medicine under the trade name of atophan in 1908 by Nicolaier and Dohrn.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P12841
Gene ID: 314322.0
Gene Symbol: Fos
Target Organism: Rattus norvegicus (Rat)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Atophan

Approved Use

It has been used extensively for gout as well as for other forms of arthritis and for the relief of pain of all types.
Doses

Doses

DosePopulationAdverse events​
485.9 mg 3 times / day multiple, oral
Dose: 485.9 mg, 3 times / day
Route: oral
Route: multiple
Dose: 485.9 mg, 3 times / day
Sources:
unhealthy, 19 years
Health Status: unhealthy
Age Group: 19 years
Sex: F
Sources:
Other AEs: Jaundice, Nausea...
Other AEs:
Jaundice
Nausea
Abdominal pain
Sources:
485.9 mg 1 times / day multiple, oral
Dose: 485.9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 485.9 mg, 1 times / day
Sources:
unhealthy, 38 years
Health Status: unhealthy
Age Group: 38 years
Sex: F
Sources:
Disc. AE: Jaundice...
AEs leading to
discontinuation/dose reduction:
Jaundice (grade 5)
Sources:
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 57 - 67 years
Health Status: unhealthy
Age Group: 57 - 67 years
Sex: F
Sources:
Disc. AE: Hepatitis...
Other AEs: Hepatic failure...
AEs leading to
discontinuation/dose reduction:
Hepatitis (acute, 2 patients)
Other AEs:
Hepatic failure (severe|grade 5, 1 patient)
Sources:
0.5 g 1 times / day multiple, oral
Dose: 0.5 g, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
Disc. AE: Hepatitis, Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Hepatitis
Agranulocytosis
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain
485.9 mg 3 times / day multiple, oral
Dose: 485.9 mg, 3 times / day
Route: oral
Route: multiple
Dose: 485.9 mg, 3 times / day
Sources:
unhealthy, 19 years
Health Status: unhealthy
Age Group: 19 years
Sex: F
Sources:
Jaundice
485.9 mg 3 times / day multiple, oral
Dose: 485.9 mg, 3 times / day
Route: oral
Route: multiple
Dose: 485.9 mg, 3 times / day
Sources:
unhealthy, 19 years
Health Status: unhealthy
Age Group: 19 years
Sex: F
Sources:
Nausea
485.9 mg 3 times / day multiple, oral
Dose: 485.9 mg, 3 times / day
Route: oral
Route: multiple
Dose: 485.9 mg, 3 times / day
Sources:
unhealthy, 19 years
Health Status: unhealthy
Age Group: 19 years
Sex: F
Sources:
Jaundice grade 5
Disc. AE
485.9 mg 1 times / day multiple, oral
Dose: 485.9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 485.9 mg, 1 times / day
Sources:
unhealthy, 38 years
Health Status: unhealthy
Age Group: 38 years
Sex: F
Sources:
Hepatitis acute, 2 patients
Disc. AE
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 57 - 67 years
Health Status: unhealthy
Age Group: 57 - 67 years
Sex: F
Sources:
Hepatic failure severe|grade 5, 1 patient
300 mg 1 times / day multiple, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, 57 - 67 years
Health Status: unhealthy
Age Group: 57 - 67 years
Sex: F
Sources:
Agranulocytosis Disc. AE
0.5 g 1 times / day multiple, oral
Dose: 0.5 g, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
Hepatitis Disc. AE
0.5 g 1 times / day multiple, oral
Dose: 0.5 g, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
PubMed

PubMed

TitleDatePubMed
A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase.
2001 Feb 26
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
2005 Mar 15
Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS.
2008 Jul
Poly[bis-(μ-hemihydrogen 2-phenyl-quinoline-4-carboxyl-ato-κN,O)silver(I)].
2009 Jan 23
Bis(μ-2-phenyl-quinoline-4-carboxyl-ato)-κO,O':O;κO:O,O'-bis-[(2,2'-bipyridine-κN,N')(2-phenyl-quinoline-4-carboxyl-ato-κO,O')cadmium(II)].
2010 Dec 4
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Patents

Patents

Sample Use Guides

The mean dose was 300 mg/day for a mean duration of 3-4 months
Route of Administration: Unknown
Cinchophen (200 ug /ml) reduced the response of the isolated guinea-pig ileum to bradykinin.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:52:41 GMT 2025
Edited
by admin
on Mon Mar 31 18:52:41 GMT 2025
Record UNII
O65C9QHG6D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CINCHOPHEN PIPERAZINE
WHO-DD  
Common Name English
4-QUINOLINECARBOXYLIC ACID, 2-PHENYL-, COMPD. WITH PIPERAZINE (1:1)
Preferred Name English
Cinchophen piperazine [WHO-DD]
Common Name English
Code System Code Type Description
EVMPD
SUB01308MIG
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
PRIMARY
CAS
855165-13-8
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID40234726
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
PRIMARY
PUBCHEM
71300650
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
PRIMARY
SMS_ID
100000084810
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
PRIMARY
FDA UNII
O65C9QHG6D
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
PRIMARY
CAS
59672-15-0
Created by admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
NON-SPECIFIC STOICHIOMETRY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY